Why Precision Alone Isn't Enough in Oncology Drug Discovery

Oncology drug discovery pipelines have never been more targeted, yet clinical failure rates are still high. The big challenge now is turning biological precision into repeatable, real-world results.

Image

Why So Many Promising Oncology Drugs Still Fail

Oncology drug discovery still fails at scale because biological precision has outpaced operational execution.

Despite advances in genomics and targeted therapies:

• Fewer than 10 per cent of oncology drugs entering clinical trials reach approval
• Late-stage failures remain common, even with strong early data
• Trial complexity continues to increase as patient populations narrow

The industry has solved for what to target. It has not solved how to deliver consistent outcomes at scale. This gap defines the current state of oncology R&D.

Image

The Realities of Precision Medicine

Precision oncology has fundamentally changed how therapies are designed and tested.

It enables:

• Identification of actionable mutations
• Biomarker-driven patient stratification
• Targeted therapies with higher response rates in selected populations

In practical terms, this has improved early-stage signal detection. Drugs are more likely to show efficacy in Phase I and II trials when patients are carefully selected.

However, this success has created new problems as it fragments the patient population.

Why Precision Increases Complexity

Precision oncology reduces variation in terms of the disease biology but introduces challenges regarding the smaller, more defined patient cohorts. Namely:

• Recruitment challenges in clinical trials
• Geographic limitations on enrolment criteria
• Longer timelines to reach statistically meaningful endpoints

At the same time, regulators expect:

• Clear biomarker validation
• Robust companion diagnostics
• Evidence of efficacy across broader populations

This means that the more precise a therapy becomes, the harder it is to prove its value at scale.

How Biomarkers Have Reshaped Oncology Pipelines

Biomarkers have become the central organising principle of oncology drug discovery, and are no longer supportive tools, defining:

• Patient selection criteria
• Trial design
• Regulatory pathways

What are biomarkers in oncology?

Biomarkers are measurable indicators that predict disease progression or treatment response.

In oncology, they serve three critical functions:

• Predictive biomarkers identify which patients are likely to respond
• Prognostic biomarkers indicate disease outcomes
• Pharmacodynamic biomarkers track treatment effects

Why do biomarkers matter strategically?

Biomarkers matter strategically as they reduce trial attrition by aligning therapies with responsive patient populations.

For example:

• Targeted therapies in biomarker-defined populations often show higher response rates in early trials
• Biomarker-enriched trials can reach endpoints faster with fewer patients

But this advantage comes with trade-offs:

• Increased reliance on diagnostic infrastructure
• Higher development costs for companion diagnostics
• Regulatory complexity for qualification

Biomarkers improve precision, but they also increase dependency on systems outside the drug itself.

Image

How AI Is Changing Drug Discovery in Oncology

AI is accelerating multiple stages of oncology drug pipelines.

Where AI delivers value

AI is most effective in:

• Target identification: Analysing genomic and proteomic datasets
• Biomarker discovery: Identifying patterns linked to treatment response
• Trial optimisation: Predicting patient recruitment and endpoint success

AI-designed molecules have already demonstrated faster progression into clinical trials, in some cases reducing early-stage timelines from years to months.

Where AI still comes up short

AI can't fix everything. AI doesn't tackle the clinical differences between individuals in a population or always meet the strict demands regulators have for evidence. And when it comes to making treatments and scaling them up, AI might not be the right answer.

In other words, AI improves input quality, but outcomes still depend on execution across the full development lifecycle.

What Are the Most Important Oncology Therapeutic Innovations?

Innovation in oncology is no longer concentrated in a single modality. It is distributed across multiple approaches.

1. Antibody-drug conjugates (ADCs)

ADCs combine targeting precision with cytotoxic payloads.

They offer:

• Improved tumour specificity
• Reduced systemic toxicity

However, they introduce complexity in:

• Manufacturing
• Stability
• Dose optimisation

2. Cell and gene therapy (CGT)

CGT approaches, including CAR-T and TCR therapies, offer:

• Highly targeted immune responses
• Potential for durable outcomes

But face challenges in:

• Tumour microenvironment resistance
• Manufacturing scalability
• Cost of goods

3. Bispecific antibodies

Bispecific antibodies engage multiple targets simultaneously.

They enable:

• Dual-pathway inhibition
• Enhanced immune activation

Yet they require:

• Complex dosing strategies
• Careful safety monitoring

4. Targeted small molecules

Targeted small molecules remain the backbone of precision oncology, even as more complex modalities gain attention. Unlike biologics, these therapies can penetrate cells and modulate intracellular signalling pathways that drive tumour growth.

They offer:

• High specificity for oncogenic mutations (e.g. kinase inhibitors)
• Oral administration, improving patient accessibility and adherence
• Established regulatory pathways and manufacturing scalability

However, their limitations are becoming more visible. Resistance mechanisms emerge quickly, often through:

• Secondary mutations
• Pathway redundancy
• Adaptive tumour signalling

This creates a cycle of successive drug development rather than durable disease control.

The strategic shift is toward:

• Combination regimens targeting multiple pathways simultaneously
• Earlier-line use in biomarker-defined populations
• Integration with real-world evidence to monitor resistance patterns

Targeted small molecules are no longer a standalone solution and are increasingly part of multi-modal strategies designed to delay resistance and extend therapeutic impact.

5. Radioligand therapies (RLTs)

RLTs combine high-precision targeting with localised radiation delivery.

They work by binding a radioactive isotope to a ligand that selectively targets tumour-associated receptors, delivering cytotoxic radiation directly to cancer cells.

They offer:

• Highly targeted tumour killing with limited systemic exposure
• Efficacy in metastatic and hard-to-treat cancers
• A differentiated mechanism compared to traditional systemic therapies

Recent clinical successes in prostate and neuroendocrine cancers have accelerated investment in this space.

However, RLTs introduce unique challenges:

• Complex supply chains due to short half-life isotopes
• Specialised infrastructure requirements for handling and administration
• Regulatory considerations spanning both drug and radiological frameworks

From a strategic perspective, RLTs represent a convergence of pharmaceutical development and nuclear medicine.

Their long-term impact will depend on:

• Scaling isotope production
• Integrating diagnostics and therapeutics (theranostics)
• Aligning global regulatory pathways

RLTs signal a shift toward hybrid therapeutic models that combine biology, physics, and precision delivery.

The common thread

All these breakthroughs make treatment more precise, but the trade-off is more complicated development, tighter regulation, and higher costs. This reinforces that innovation alone does not guarantee success because execution really determines outcomes.

Where Do Oncology Pipelines Break Down?

The failure points in oncology drug discovery have changed. 

Historical bottlenecks:

• Target identification
• Mechanism validation

Current bottlenecks:

• Trial design complexity
• Patient recruitment
• Data integration across systems
• Regulatory alignment

This shift explains why more drugs reach clinical trials but approval rates have not increased proportionally.

Image

What Should Pharmaceutical Leaders Prioritise?

The next phase of oncology drug discovery will be defined by integration, not innovation.

Leaders should focus on three priorities:

1. Designing trials for reality, not theory

Trial design must reflect:

• Real-world patient diversity
• Operational constraints in recruitment
• Variability in clinical practice

Adaptive trial design and decentralised models will become standard, not optional.

2. Aligning biomarkers with commercial strategy

Biomarkers should not only guide clinical decisions, but also:

• Support market access
• Demonstrate value to payers
• Enable scalable patient identification

Failure to align biomarkers with commercial realities limits long-term impact.

3. Integrating data across the lifecycle

Data fragmentation remains a major barrier.

Successful organisations will connect preclinical and clinical data, as well as real-world evidence to allow:

• Better decision-making
• Faster discovery and development iteration
• Stronger regulatory submissions

What Success Looks Like in 2026 and Beyond

Success in oncology drug discovery is no longer defined by scientific breakthroughs alone.

It requires precision targeting and discipline in execution, with integration across systems.

Those organisations that can translate that science into consistent, scalable outcomes, not just those with the most advanced science, are more likely to succeed.

Conclusion: Precision Needs Execution

Oncology drug discovery has entered a phase where precision is necessary but insufficient. The real differentiator is the ability to execute across increasingly complex biological, clinical, and regulatory systems.

Pharmatica exists to interpret these shifts, providing decision-makers with the validated intelligence needed to turn innovation into outcomes in the most complex therapeutic area in pharmaceutical development.

Pharmatica: Insight. Connection. Impact.